Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma Inc (BBIO) news coverage focuses on clinical trial results, regulatory developments, and pipeline updates for the company's genetic disease and cancer therapies. As a commercial-stage biotechnology company with multiple drug development programs, BridgeBio generates news through data readouts from ongoing clinical trials, FDA interactions, product approvals, and commercial performance metrics for marketed therapies.
Investors following BridgeBio news will find announcements related to Phase 1, Phase 2, and Phase 3 trial enrollments and results, presentations at medical conferences, regulatory submissions and decisions, patent developments, and business development activities. The company also reports quarterly financial results that include research and development expenses, commercial revenue from approved products, cash positions, and updated clinical timelines for pipeline programs.
Key news categories include cardiovascular disease programs, rare genetic disorder therapies, oncology candidates, partnership announcements, manufacturing agreements, and intellectual property milestones. Given the binary nature of biotechnology development, where clinical trial results and regulatory decisions can significantly impact company trajectory, staying informed about BridgeBio's pipeline progress helps investors understand the company's execution against development plans and commercial strategies.
BridgeBio Pharma announced the initiation of a Phase 1/2 clinical trial for BBP-398, an investigational SHP2 inhibitor, in combination with OPDIVO for treating patients with KRAS-mutated non-small cell lung cancer (NSCLC). The trial aims to evaluate the safety and preliminary efficacy of this combination, targeting a significant unmet medical need as KRAS mutations are present in approximately 27% of NSCLC cases. If successful, this therapy could enhance treatment options for patients with these mutations. Initial data from this trial is expected later in 2023.
BridgeBio Pharma will present preliminary data on its muscle tissue-based bioassay for LGMD2I patients at the MDA 2023 Annual Meeting from March 19-22 in Dallas, Texas. The company will discuss 15-month Phase 2 data and the design of its Phase 3 clinical trial for BBP-418, expected to start in mid-2023. An oral presentation will be held on March 20, featuring results from the ongoing Phase 2 trial. An investor call with Dr. Jeffrey Rosenfeld is scheduled for March 21 at 8:30 am ET, discussing findings and study updates.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced an underwritten public offering of 8,823,530 shares at $17.00 per share, targeting gross proceeds of approximately $150 million. The offering includes a 30-day option for underwriters to purchase an additional 1,323,529 shares. The offering is managed by Goldman Sachs, Evercore ISI, Morgan Stanley, and KKR Capital Markets. Closing is expected around March 10, 2023. The shares are offered under an effective shelf registration statement filed with the SEC. This press release does not constitute an offer to sell or solicit any offers to buy these securities in unlawful jurisdictions.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) has initiated an underwritten public offering of $150 million in common stock, with an additional $22.5 million option for underwriters. The offering is under the management of Goldman Sachs, Evercore, and Morgan Stanley and is subject to market conditions. The shares are offered under an effective shelf registration statement filed with the SEC in July 2020. A preliminary prospectus supplement detailing the offering will be filed shortly. This announcement does not serve as an offer to sell or solicit purchases in jurisdictions where it would be illegal. BridgeBio is dedicated to advancing treatments for genetic diseases and cancers.
BridgeBio Pharma announced positive results from the PROPEL2 Phase 2 trial of infigratinib in children with achondroplasia. Key findings include:
- In Cohort 5, a mean increase in annualized height velocity (AHV) of +3.03 cm/yr (p = 0.0022) was observed at the highest dose (0.25 mg/kg once daily).
- 80% of participants were responders with an average AHV increase of +3.81 cm/yr.
- Median absolute AHV reached 7.6 cm/yr.
- Infigratinib showed a clean safety profile with no treatment-related adverse events.
- BridgeBio is now enrolling for a pivotal Phase 3 trial and exploring infigratinib for hypochondroplasia.
BridgeBio Pharma (Nasdaq: BBIO) announced an investor call on March 6, 2023, at 7:30 am ET to discuss Phase 2 Cohort 5 data from the PROPEL2 clinical trial of infigratinib, targeting achondroplasia. Infigratinib is designed to inhibit fibroblast growth factor receptor 3 (FGFR3), addressing a genetic condition affecting ~55,000 in the US and EU. This genetic disorder can lead to serious health complications, emphasizing the importance of continued research and treatment innovation. For more details, visit BridgeBio's website.
BridgeBio Pharma (Nasdaq: BBIO) reported its Q4 and full-year 2022 financial results, ending the year with $466.2 million in cash and equivalents, down from $787.7 million in 2021. The company incurred a net loss of $484.7 million for the year, with revenues decreasing to $77.6 million from $69.7 million. Key clinical trials continue, including the Phase 3 ATTRibute-CM trial for acoramidis, with topline data expected mid-2023, and the PROPEL 2 trial for infigratinib, expected to report in March 2023. Operating expenses decreased due to restructuring efforts, with total operating costs at $589.9 million.
On February 13, 2023, BridgeBio Pharma (Nasdaq: BBIO) granted 11 new employees restricted stock units totaling 59,800 shares of common stock. These awards were made under the company’s 2019 Inducement Equity Plan, adhering to Nasdaq Listing Rule 5635(c)(4). BridgeBio, a biopharmaceutical firm founded in 2015, focuses on creating medicines for genetic diseases and cancers, leveraging advances in genetic medicine. The company’s pipeline ranges from early-stage research to advanced clinical trials.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced a roundtable discussion on February 16, 2023, focusing on the medical and social implications of achondroplasia. The discussion will feature Dr. Melita Irving, a clinical geneticist at Guy's and St Thomas' NHS Foundation Trust, who is known for her expertise in genetic and rare conditions, particularly skeletal dysplasia. The event aims to shed light on the challenges faced by individuals with achondroplasia and explore new treatment options. The live webcast will be accessible on the BridgeBio website, with a replay available for 90 days.
BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company, announced participation in several investor conferences in February and March 2023. Key events include the SVB Securities Global Biopharma Conference on February 14 at 2:20 PM ET, the Goldman Sachs Bus Tour on March 1 at 8:00 AM PT, and the Cowen 43rd Annual Healthcare Conference on March 8 at 10:30 AM ET.
Live webcasts will be available on the company's website, with replays accessible for 90 days post-event. Founded in 2015, BridgeBio focuses on developing transformative medicines for genetic diseases and cancers.
FAQ
What is the current stock price of Bridgebio Pharma (BBIO)?
What is the market cap of Bridgebio Pharma (BBIO)?
